Research and Clinical Trials on Bupropion (Amfebutamone, Wellbutrin, Zyban)
This list of current clinical research trials on Bupropion (Amfebutamone, Wellbutrin, Zyban) is followed by a short set of abstracts from the most recent research articles published on the drug.
Bupropion (Amfebutamone, Wellbutrin, Zyban) Clinical Research Trials
From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Bupropion (Amfebutamone, Wellbutrin, Zyban).
- Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression
Status: Recruiting, Condition Summary: Depression - Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 2: Do Varenicline (Chantix) and Bupropion (Zyban) Change Alcohol Drinking?
Status: Recruiting, Condition Summary: Alcohol Drinking - The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior
Status: Recruiting, Condition Summary: Smoking Lapse Behavior - A Trial of Wellbutrin for Crohn's Disease
Status: Completed, Condition Summary: Crohn Disease - Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
Status: Recruiting, Condition Summary: Smoking Cessation - Concurrent Bupropion / Varenicline for Smoking Cessation
Status: Recruiting, Condition Summary: Nicotine Dependence - Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation
Status: Recruiting, Condition Summary: Nicotine Dependence - Combining Varenicline and Bupropion for Smoking Cessation
Status: Recruiting, Condition Summary: Smoking Cessation - Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)
Status: Not yet recruiting, Condition Summary: Non Small Cell Lung Cancer - Pharmacogenetics, Emotional Reactivity and Smoking
Status: Active, not recruiting, Condition Summary: Tobacco Use Disorder; Smoking Cessation
Get These Clinical Trials as a Newsfeed
Bupropion: 
Current Research Literature on Bupropion (Amfebutamone, Wellbutrin, Zyban)
Here are abstracts for some of the latest research articles to have appeared on Bupropion (Amfebutamone, Wellbutrin, Zyban):
Effects of Menthol on the Pharmacokinetics of Bupropion Among Black Smokers.
Nicotine Tob Res. 2012 Feb 8;
Okuyemi KS, Faseru B, Reed GA, Cox LS, Bronars CA, Opole I, Whembolua GL, Mayo MS, Ahluwalia JS, Benowitz NL
INTRODUCTION: Despite the widespread use of mentholated cigarettes, lower cessation rates, and disproportionately high smoking-related morbidity among Blacks, the possible role of menthol in smokers' response to pharmacotherapy has not been well-studied. This study examined the effects of menthol on the pharmacokinetic (PK) profiles of bupropion and its principal metabolites, hydroxybupropion, threohydrobupropion, and erythrohydrobupropion among Black smokers. METHODS: After a 7-day placebo run-in period, participants received 150 mg bid sustained-release bupropion for 20-25 days. Blood samples were drawn for PK analysis on 2 occasions, 10-15 days after the commencement of bupropion while participants were still smoking (smoking phase) and at days 20-25 when they were asked not to smoke (nonsmoking phase). RESULTS: 18 smokers of nonmenthol cigarettes and 23 smokers of menthol cigarettes were enrolled in this study. No differences were found by menthol smoking status in the Cmax and area under the plasma concentration versus time curve (AUC) of bupropion and its metabolites in the smoking or nonsmoking phases. However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034). No significant differences were found in the metabolite/bup ratios between smoking and nonsmoking conditions among nonmenthol smokers.Conclusions:We did not find a significant effect of menthol compared with nonmenthol cigarette smoking on the PKs of bupropion and metabolites at steady state. More research is needed to advance the understanding of mechanisms underlying disparities in smoking cessation outcomes related to smoking of menthol cigarettes.
Nicotine Tob Res. 2012 Feb 7;
Borland R, Partos TR, Cummings KM
INTRODUCTION: Randomized, controlled trials typically indicate stop-smoking medications (SSMs: e.g., Varenicline, Bupropion, and over-the-counter nicotine replacement therapies) to be effective, whereas cross-sectional community-based studies have found them to be less effective, ineffective, or even associated with higher risk of relapse. Consequently, some critics have suggested SSMs have no useful applications in "real-world" settings. This discrepancy may, however, be due to systematic biases affecting cross-sectional survey outcomes. Namely, failed quit attempts where SSMs were used may be better recalled than failed unassisted attempts. Moreover, smokers who choose to quit using SSMs may be more addicted and thus less likely to succeed. Either of these factors would lead to an over-representation of failed quit attempts among SSM users in cross-sectional surveys even if there were real benefits. METHODS: We report on data from the International Tobacco Control 4-country cohort study to examine the relationship between SSM use, level of nicotine addiction, and the reported date since the start of participants' (N = 1,101) most recent quit attempt. RESULTS: The last quit attempt was reported to have begun longer ago among participants who used SSMs than those who did not. Scores on the Heaviness of Smoking Index, measuring addiction severity, were also higher among SSM users, with no interactions.Conclusion:Better recall of quit attempts and stronger addiction to nicotine are two characteristics found more often among smokers using SSMs compared with self-quitters, which could potentially bias the assessed effects of SSMs on cessation outcomes in cross-sectional surveys.
Pharmazie. 2011 Dec; 66(12): 924-8
Hu L, Wang Z, Xu R, Ma J, Wang X, Zhang X
A sensitive and selective liquid chromatograpy-mass spectrometry method for the determination of bupropion and its main metabolite, hydroxubupropion, in rat plasma was developed and validated. After addition of carbamazepine as internal standard (IS) and precipitation of protein with acetonitrile, the plasma samples were analyzed on an Agilent Zorbax SB-C18 (2.1 mm x 50 mm, 3.5 microm) column at 30 degrees C, with acetonitrile-0.1% formic acid as mobile phase at a flow rate of 0.4 mL min(-1). The detection was carried out in the selective ion monitoring mode with a positive electrospray ionization interface. The calibration curve was linear over the 10-2000 ng mL(-1) for bupropion and 5-1000 ng mL(-1) for hydroxybupropion in plasma. RSD of inter-day and intra-day precision was less than 7% for bupropion, 9% for hydroxybupropion. The developed method was successfully applied to pharmacokinetic studies after single intragastric administration of bupropion 15 mg kg(-1) to rats.
Ann Clin Psychiatry. 2012 Feb; 24(1): 23-37
Bond DJ, Hadjipavlou G, Lam RW, McIntyre RS, Beaulieu S, Schaffer A, Weiss M
Patients with bipolar disorder (BD) and major depressive disorder (MDD) experience adult attention-deficit/hyperactivity disorder (ADHD) at rates substantially greater than the general population. Nonetheless, ADHD frequently goes untreated in this population.We reviewed the literature regarding the management of adult ADHD in patients with mood disorders. Because a limited number of studies have been conducted in adults, our treatment recommendations also are partly informed by research in children and adolescents with BD+ADHD or MDD+ADHD, adults with ADHD, and our clinical experience.In individuals with mood disorders, ADHD is best diagnosed when typical symptoms persist during periods of sustained euthymia. Individuals with BD+ADHD, particularly those with bipolar I disorder (BD I), are at risk for mood destabilization with many ADHD treatments, and should be prescribed mood-stabilizing medications before initiating ADHD therapies. Bupropion is a reasonable first-line treatment for BD+ADHD, while mixed amphetamine salts and methylphenidate also may be considered in patients determined to be at low risk for manic switch. Modafinil and cognitive-behavioral therapy (CBT) are second-line choices. In patients with MDD+ADHD and moderate to severe depression, MDD should be the treatment priority, whereas in mildly depressed or euthymic patients the order may be reversed. First-line treatments for MDD+ADHD include bupropion, an antidepressant plus a long-acting stimulant, or an antidepressant plus CBT. Desipramine, nortriptyline, and venlafaxine are second-line options.Clinicians should be vigilant in screening for comorbid ADHD in mood disorder patients. ADHD symptoms can respond to appropriately chosen treatments.
Sertraline-associated hyponatremia and subsequent tolerability of bupropion in an elderly woman.
Prim Care Companion CNS Disord. 2011; 13(5):
Cerimele JM, Robinson LA
